IPCI Stock DD Intellipharmaceutics International Inc. 11/04/2014

Posted On: 11/04/2014 9:50:06 AM

Post# of 250676

Posted By: Rosner

IPCI Intellipharmaceutics International Inc. $IPCI Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=IPCI&...mp;yt0=Go!

Last Updated: 11/04/2014 08:50:06

Current Price and Quotes
Last Price
Previous Close Open
Daily Range - 52wk Range -
Volume Dividend
Average Vol (30d) Yield

Financials
Period Ending Nov 30, 2013 Nov 30, 2012 Nov 30, 2011 Nov 30, 2010
Total Revenue 1,527 107 502 1,459
Cost of Revenue - - - -
Gross Profit 1,527 107 502 1,459
Operating Expenses

Research and Development 5,076 5,992 5,126 4,533
Sales, General and Admin. 2,873 3,672 2,925 2,699
Non-Recurring Items - 107 - 36
Other 397 452 227 243
Operating Income (6,819) (10,117) (7,777) (6,052)
Income From Continuing Operations

Add'l Income/Expense Items (4,246) 4,044 5,338 390
Earnings Before Interest and Tax (11,065) (6,073) (2,439) (5,663)
Interest Expense 430 63 2,441 98
Earnings Before Tax (11,495) (6,137) (4,880) (5,761)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (11,495) (6,137) (4,880) (5,761)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (11,495) (6,137) (4,880) (5,761)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (11,495) (6,137) (4,880) (5,761)

Recent News
Source
Oct 27, 2014 Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification GlobeNewswire
Oct 22, 2014 Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release) GlobeNewswire
Oct 15, 2014 Intellipharmaceutics Announces Third Quarter 2014 Results GlobeNewswire
Oct 15, 2014 IntellipharmaCeutics' cash burn improves modestly Seeking Alpha
Oct 15, 2014 IntelliPharmaCeutics<span class="Apple-tab-span" style="white-space:pre"> </span> beats by $0.04, beats on revenue Seeking Alpha
Oct 15, 2014 Profound Medical Appoints Shameze Rampertab as Chief Financial Officer GlobeNewswire
Sep 30, 2014 Intellipharmaceutics Announces Resignation of Chief Financial Officer GlobeNewswire
Aug 28, 2014 Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology GlobeNewswire

(0)